Indefinite Delivery Contract SPE2DB20D9636

The Defense Logistics Agency (DLA) awarded a $499,999,999 Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a wide range of pharmaceutical products and medical supplies. The IDC, under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical needs of military health facilities worldwide. The contract, which does not have a set-aside designation, covers various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. Delivery orders issued under the IDC include $2,701.36 for Hemabate 250 mcg/mL, $8,576.28 for Nexplanon 68 mg implants, $203 for FreeStyle Lite test strips, $5,899.18 for Praxbind 5g dose, $323 for levofloxacin 500 mg/100 mL solution, and $5,078.46 and $6,034.20 for Prime Vendor Pharmaceutical Branch-Philadelphia products. The IDC is valid through December 31, 2025, with a place of performance in Park Ridge, Illinois, where DMS Pharmaceutical Group Inc. is headquartered.

The DLA, which manages the global supply chain for the U.S. military, awards contracts and delivery orders to maintain necessary medical supplies and ensure the readiness and well-being of military personnel. Through this IDC, DMS Pharmaceutical Group Inc. is positioned as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.